Back

The effect of 6-month treatment with coenzyme Q10 on endothelial, vascular and myocardial function in patients with nonalcoholic fatty liver disease.

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Liver metabolism and heart disease Nutrition, Malnutrition and Heart Disease ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Ignatios Ikonomidis

National & Kapodistrian University of Athens, Athens (Greece)

6 More presentations in this session

Presentation thumbnail
Serum lipid profiles and uptake of lipid-lowering therapy in patients with premature atherosclerotic cardiovascular disease (ASCVD) in comparison to older patients with ASCVD
Professor T. Tan (Sydney, AU)
Abstract Slides Video
Presentation thumbnail
Angioprotein-like 3 and atheroma progression in statin-treated type 2 diabetic patients with coronary artery disease: the pre-specified analysis from the OPTIMAL randomized controlled trial.
Doctor S. Kitahara (Kashiwa, JP)
Abstract Slides Video
Presentation thumbnail
PCSK9 inhibitors in HIV patients with dyslipidemia
Doctor S. Datla (Cleveland, US)
Abstract Slides Video
Presentation thumbnail
Circulating levels of amyloid-beta (1-40) peptide associate with cardiometabolic traits and risk for metabolic dysfunction-associated steatotic liver disease
Doctor E. Aivalioti (Athens, GR)
Abstract Slides Video
Presentation thumbnail
The association of steatotic liver disease with recurrent ischemic events in patients with chronic coronary syndrome: a multicenter cohort study
Doctor G. Zeng (Beijing, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Liver metabolism and heart disease

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Nonalcoholic fatty liver disease worsens cardiac repair after myocardial infarction
thumbnail
Congress Presentation
Pro-B-type natriuretic peptide strongly predicts major cardiovascular events and cardiovascular mortality in coronary artery disease patients with NAFLD as well as in those without NAFLD
thumbnail
Congress Presentation
Effects of sodium-glucose contrasporter-2 inhibitors and glucagon-like peptide-1 receptor agonists on arterial stiffness, coronary flow reserve and liver steatosis in diabetes

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources